Amyotrophic Lateral Sclerosis (ALS) Clinical Trial
Official title:
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of ALS pathology, treatment targets, disease progression, and anatomical differences between different disease phenotypes. This pilot project is tailored to produce imaging tools that will allow researchers to conduct future ALS clinical trials more efficiently which may in turn impact the pace for ALS drug discovery.
In this trial, approximately 200 subjects will participate in this study from 2 Northeast ALS
Consortium (NEALS) centers in the United States. Fifty (50) ALS participants will be age and
gender matched to 50 participants with no known neurological disorder (healthy controls). Of
these, twenty five (25) ALS participants will be age (±5 years) gender and binding affinity
(TSPO) matched to 25 healthy controls.
During the enrollment period 200 participants will be screened and 100 participants will
ultimately be scanned. There will be a maximum allowed time of 45 days between the screening
and baseline visits (1st scan). All 100 subjects will undergo MRI scanning and clinical
assessment at the Baseline Visit. Healthy control participants will have no further follow-up
visits once they have completed their participation in the screening and baseline visits.
Only 50 subjects from this sample will undergo PET scanning. The ALS participants will return
for follow-up MRI scanning and clinical assessments every three months and follow-up PET
scanning every 6 months over a 12-month period.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02365922 -
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
|
||
| Completed |
NCT01699451 -
DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida
|
||
| Completed |
NCT04577404 -
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 3 | |
| Terminated |
NCT03580616 -
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
| Completed |
NCT01884571 -
Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Completed |
NCT00244244 -
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
|
Phase 2 | |
| Active, not recruiting |
NCT00420719 -
Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)
|
N/A | |
| Completed |
NCT02936635 -
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
|
Phase 3 | |
| Withdrawn |
NCT04055532 -
Biomarkers in Neurodegenerative Diseases
|
||
| Completed |
NCT03645031 -
Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
|
N/A | |
| Completed |
NCT01786603 -
Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Completed |
NCT01592552 -
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
|
||
| Completed |
NCT00403104 -
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Recruiting |
NCT02424669 -
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients
|
N/A | |
| Completed |
NCT02017912 -
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
|
Phase 2 | |
| Completed |
NCT01366027 -
PRISM Registry: Pseudobulbar Affect Registry Series
|
N/A | |
| Completed |
NCT00330681 -
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
|
Phase 3 | |
| Completed |
NCT00876772 -
Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06351592 -
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
|
Phase 1 |